<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522830</url>
  </required_header>
  <id_info>
    <org_study_id>2020-04-0311</org_study_id>
    <nct_id>NCT04522830</nct_id>
  </id_info>
  <brief_title>A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19</brief_title>
  <acronym>BTL-TML-COVID</acronym>
  <official_title>A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beech Tree Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwich Clinical Research Associates Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Curavit Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beech Tree Labs, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of
      SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and
      viral levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean duration and severity of disease</measure>
    <time_frame>Two days</time_frame>
    <description>Change from baseline in the physical component summary of the short form-36 Quality of Life Instrument</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events</measure>
    <time_frame>Baseline through 14 days</time_frame>
    <description>AEs will be assessed by the investigator as to severity, duration and relationship to treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>BTL-TML-COVID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTL-TML-COVID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTL-TML-COVID</intervention_name>
    <description>Sublingual dosing of BTL-TML-COVID on day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment, then every hour for the balance of the day until bedtime.
Days 2 and 2 - 1 drop every 2-3 hours for a total of 6 times during the day. Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.</description>
    <arm_group_label>BTL-TML-COVID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sublingual dosing of Placebo on day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment, then every hour for the balance of the day until bedtime.
Days 2 and 2 - 1 drop every 2-3 hours for a total of 6 times during the day. Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years of age or older

          -  Provide written informed consent

          -  Have a SAR-COV-19 diagnostic test with positive results

          -  Have a history of one or more comorbid conditions i.e., chronic respiratory diagnosis,
             hypertension and/or diabetes

        Exclusion Criteria:

          -  Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy

          -  Subjects currently hospitalized

          -  Subjects with a diagnosis of immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duane Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Truax-Bellows</last_name>
    <role>Study Director</role>
    <affiliation>Norwich Clinical Research Associates (NCRA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Hatch</last_name>
    <phone>(401) 273-2060</phone>
    <email>tomhatch@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intermountain Clinical Reserach</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DeAnn Sims</last_name>
      <phone>801-553-2379</phone>
      <email>deann@icrtrials.com</email>
    </contact>
    <investigator>
      <last_name>Duane Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment for COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

